Canada’s “me first” COVID-19 vaccine strategy may come at the cost
Elevating national interests over global health slows progress and limits global capacity to pool resources, with devastating effects.
When the throne speech was delivered on Sept. 23, Canada had already committed over $1 billion in advance purchase agreements with five drug companies for a minimum of 154 million vaccine doses, if and when these candidate vaccines are proven effective and safe. Two days later, Canada inked another agreement with another company for 20 million more doses, hedging its bets on which of the vaccine contenders will be the first to arrive.
In doing so, Canada joins the premier league of the vaccine nationalists, a handful of rich countries that has pre-purchased (so far) more than half the world’s expected short-term supply of vaccines.
It is understandable that countries want to ensure their ability to protect their citizens’ health. But most of the world’s population lives in countries without the same financial resources to play the global “me first” vaccine contest. Efforts to elevate national interests over collective global health result in slower progress and limited global capacity to pool resources, while placing the interests of wealthy countries over others, with devastating effects.
Recent modelling compared two scenarios for allocating the first three billion doses of a vaccine that is 80 per cent effective. The “unco-operative” scenario – in which two billion doses went straight to high-income countries, and the rest to everybody else – would lead to 28 per cent more deaths than a “co-operative” scenario, in which the three billion doses are distributed globally, proportional to population size.
What can Canada do?
To begin, our pledge to the World Health Organization’s COVAX Facility’s Advanced Market Commitment (AMC). should, at a minimum, match what we invest in procuring vaccine for use within Canada. The facility manages the world’s largest and most diverse portfolio of vaccine candidates. High-income countries like Canada that join COVAX have the option to purchase approved vaccines through the facility, even if they have already entered into bilateral purchase agreements with vaccine companies. On Sept. 25, Canada announced that it would do so, committing $220 million to purchase 15 million more vaccine doses from the facility if and as they are approved.
Arguably of more importance, the facility’s AMC will provide vaccines to more than 90 eligible poorer countries unable to afford them on their own. The AMC needs to raise $2 billion by December to do so, with the short-term goal of immunizing three per cent of all COVAX countries’ populations. As of Sept. 21, only $700 million had been promised. On Sept. 25, Canada committed $220 million to the AMC, on top of $25 million it had already given. This is welcome and commendable, but it is also inadequate.
The AMC’s longer-term aim is to reach 20 per cent _ a goal that will allow health-care workers and vulnerable populations in poor countries to receive vaccines _ but this will depend entirely on how generously high-income countries, philanthropists and drug companies donate to the AMC.
Much more AMC funding is needed now, and going forward. We argue that Canada should commit a dollar-per-dollar amount to the AMC based on what it spends on its own vaccine purchases. This would mean providing up to $1 billion more than its current AMC pledge, with funds flowing through our country’s official development assistance (ODA) envelope. Canada has global obligations under international declarations to do so.
Canada says it is a voice for equity and human rights, at home and on the global stage. Actions speak louder than words. Canada in recent years has not been particularly generous in its overseas assistance. We ranked 17th out of 30 of the OECD club of donor nations in 2019, contributing just 0.27 per cent of our gross national income, with no forseeable increase. A $1 billion immediate AMC top-up would still not lift us to our long-pledged 0.7 per cent ODA target.
One billion dollars sounds like a lot of money. But it is only one-fifth the amount the federal government has borrowed weekly since March from the Bank of Canada (which it owns) to finance its pandemic assistance programs. Most less-endowed countries lack the same ability to borrow indefinitely from their own central banks and instead must turn to foreign creditors, with the debt-burden risks that entails. Or do without.
According to the CEO of the world’s largest vaccine maker, the Serum Institute of India, even with expanded global capacity, it may take until 2024 before there are enough doses for the world’s population. In addition to ensuring more generous support for the COVAX Facility, Canada can also ramp up its own vaccine manufacturing capacity. It’s already on a pathway to do so, with the government’s $126-million investment for a new facility in Montreal. The facility’s goal is to produce two million vaccine doses per month for domestic use by summer 2021.
Why not double-down on this investment, and reserving half the output for AMC use to meet urgent global needs? This would signify to all Canadians the importance of a collective response to this pandemic.
Public health is global
As the world eagerly awaits arrival of an effective vaccine, it’s important to remember three things. First, the longer-term effectiveness of any vaccine will remain uncertain for some time. Second, even if herd immunity to COVID-19 eventually develops, there will almost certainly be another novel infection in the not-so-distant future. Third, one way to deal with both future pandemic risks and the present short supply of COVID-19 vaccine is to embrace the range of non-pharmaceutical interventions that can flatten and even contain infectious curves. This is especially so in those countries that are home to the half of humanity who still lack access to essential health care.
All countries need stronger public health workforces: more nurses, testers, contact tracers and community health workers. All countries need universal health coverage, one of the Sustainable Development Goal targets to which the world (Canada included) committed to achieve by 2030. But it is the poorer half of humanity who needs this more urgently.
So, if Canada and other rich countries in their vaccine nationalism continue inadvertently to crowd out access for poor countries, they should compensate by massively underwriting the investments such countries need to provide the social protection, income support and food security basic to their citizens’ health, and to strengthen their health systems with the public health capacity to suppress outbreaks as they arise.
It is in our own national interest to do so. As the Sept. 23 throne speech concluded:
“We cannot eliminate this pandemic in Canada unless we end it everywhere.”
Ronald Labonte receives funding from Canadian Institutes of Health Research, Social Sciences and Humanities Research Council, International Development Research Centre, National Institutes of Health, National Medical Health and Research Council, and Australian Research Council.
Katrina Plamondon receives funding for research and knowledge translation activities from the Michael Smith Foundation for Health Research, the Canadian Institutes for Health Research, the Vancouver Foundation, the Canadian Partnership for Women and Children’s Health-Canadian Collaborative for Global Health, the BC Support Unit, and the Kelowna General Hospital Foundation.
Mira Johri is on the Board of Directors of the Canadian Coalition for Global Health Research and serves as an independent expert to Gavi, the Vaccine Alliance. Her research is currently funded by the Canadian Institutes of Health Research, the Bill and Melinda Gates Foundation, IC-IMPACTS Network Centre of Excellence, and Grand Challenges India.
Srinivas Murthy receives research funding from the Canadian Institutes of Health Research and the Wellcome Trust. He receives salary support through the University of British Columbia as the Health Research Foundation chair in pandemic preparedness research.
This article is republished from The Conversation under a Creative Commons license. Disclosure information is available on the original site. Read the original here.